Peptide-powered wellness.
Direct-pay telehealth, 48 states + DC.
Medical Weight Loss
Physician-supervised evaluation for a GIP/GLP-1 receptor agonist option.
Overview
Tirzepatide is a dual GIP/GLP-1 receptor agonist. Several FDA-approved branded tirzepatide products exist; TelePeptide does not sell or distribute branded products. Where clinically appropriate after individualized medical evaluation, a licensed physician may prescribe a compounded preparation containing tirzepatide tailored to the specific patient. The compounded preparation is dispensed by a licensed 503A or 503B compounding pharmacy. Compounded preparations are NOT FDA-approved drugs, are NOT generic versions of any branded product, and are not represented as therapeutically equivalent.
Administration
If prescribed, self-administered per the physician's instructions.
Frequency
As directed by the prescribing physician.
Program Track
Medical Weight Loss
Pricing
from $214 /mo
Annual prepay rate · monthly billing $249/mo · all-inclusive
How It Works
Tirzepatide is a synthetic peptide that acts at the GIP and GLP-1 receptors. Mechanism information is provided for general education. Whether tirzepatide (in any form) is clinically appropriate for an individual patient is a determination made by the prescribing physician based on full medical history and evaluation.
Benefits
Eligibility
Adults seeking physician-supervised medical weight-management evaluation. Eligibility, dose, and form are determined individually by your prescribing physician based on full medical history. Not appropriate for patients with certain contraindications including a personal or family history of medullary thyroid carcinoma, MEN2 syndrome, or known hypersensitivity.
Clinical supervision required. Eligibility for this program is determined by your prescribing physician based on individual medical history. Not all patients will qualify.
FAQ
No. Compounded preparations are not FDA-approved drugs, are not generic versions of branded medications, and are not represented as therapeutically equivalent. Whether a compounded preparation is appropriate for a given patient is an individualized clinical decision.
GLP-1 receptor agonists may cause nausea, vomiting, diarrhea, constipation, decreased appetite, and other effects, particularly during dose escalation. Rare but serious risks (including pancreatitis and thyroid-related concerns) will be reviewed with you by your physician before any prescription is issued.
Complete a brief online intake — a licensed physician will review your goals and confirm eligibility.